The albumin–bilirubin grade improves hepatic reserve estimation post‐sorafenib failure: implications for drug development

Abstract

The ALBI grade at sorafenib discontinuation identifies a subset of patients with prolonged stability of hepatic reserve and superior survival. This may allow improved patient selection for second-line therapies in advanced HCC.